Can a new drug combo outperform standard chemo for Hard-to-Treat lymphoma?
NCT ID NCT06792253
First seen Aug 19, 2026 · Last updated Aug 19, 2026
Summary
This Phase 3 trial is testing whether the experimental drug BEBT-908, when combined with rituximab, can improve survival in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Participants will be randomly assigned to receive either this new combination or a standard chemotherapy regimen chosen by their doctor. The study aims to see if the new approach offers better outcomes than current treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ifupinostat hydrochloride (BEBT-908) combined with rituximab
- What this could lead to
- If successful, this combination could offer a new, more effective treatment option for people with relapsed or refractory diffuse large B-cell lymphoma, potentially improving survival.
- What could go wrong
- This is a Phase 3 trial, but the experimental drug may not prove better than standard chemo, and side effects could be significant. Results are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a cancer biopsy predict who responds to a new immunotherapy?
- Can a reshaped chemo combo tame lymphoma with fewer side effects?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- New drug cocktail aims to tackle tough lymphoma
- Radiation and immunotherapy team up against hard-to-treat lymphoma